Kick off your day with Donor to Dose, a fresh series of expert conversations exploring the critical science and strategies behind successful cell and gene therapy manufacturing.
In this first session, Excellos Chief Scientific Officer Dr. Robert Tressler dives into Excellos360™, our innovative multiparametric analysis platform that evaluates T cell metabolism, function, and stemness to deliver a unified metric for prescreening starting material. Learn how combining data science with biological insight helps therapy developers make smarter upstream decisions that improve outcomes downstream.
Watch now to gain practical insights from the CDMO trenches—and stay tuned for future sessions unpacking the latest advances shaping the future of cell and gene therapy.
Contact us to continue the conversation and explore how Excellos can support your program.
